CClinicalTrials.gg
CompletedNCT04281043QoLUpdated Apr 12, 2023

Quality of Life After Robotic Surgery for Endometrial Cancer

An observational study in Quality of Life, Endometrial Cancer and Surgery--Complications, sponsored by Sahlgrenska University Hospital. Completed at 1 site in Sweden. Open to female participants aged 18 Months and older. Per ClinicalTrials.gov, last updated 2023-04-12.

Sponsored by Sahlgrenska University Hospital · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
64
Ages
18 Months and older
Sex
Female
01

Study summary

The purpose of this study is to investigate how robotic assisted laparoscopic surgery affects the quality of life of women who are treated with primary surgery for endometrial cancer. So far, very little has been published and basically no long-term follow-up.

Included patients respond to questionnaires preoperatively, 2 weeks after surgery and 3 months and 12 months after surgery.

Each patient thus answers the questionnaires (the same) on four occasions. The questionnaires used are validated and used extensively internationally. The first survey has two parts, QLQ30 and the module for endometrial cancer EN24. In addition the study includes use PHQ -9 and GAD 7.

Read the detailed description

Objective: In a pilot study to prospectively analyze the quality of life using QLQ-C30, EN-24, PHQ-9 and GAD7 in women undergoing primary surgery with robotic assisted laparoscopy for corpus cancer before and up to one year after surgery.

The study aims to describe how, to what extent and when in relation to primary surgery women's quality of life is affected after the diagnosis of endometrial cancer. The long-term goal of the work is to be able to deploy any resources if needs exist, and in this case at a time when they are most useful, to promote the quality of life of the affected women.

Question: How and when is the quality of life of women undergoing surgery for endometrial cancer affected? Is there any particular area / domain that is affected more than others and is this impact persistent over time? Method: The international and validated survey, QLQ-C30 with the addition of EN24, developed by the European Organization for Research and Treatment of Cancer (EORTC) for quality of life measurement specifically for endometrial cancer in addition to PHQ-9 and GAD7 to evaluate depression and anxiety symtoms, is planned to be used just before primary surgery, 1-2 weeks, 3 months and 1 years postoperatively.

Referens to the QLQ30 questionnaire below.

Patients are included at Department of Obstetrics and Gynecology, Sahlgrenska University Hospital, Gothenburg, Sweden for one year.

All patients included should give their oral and written consent. All data will be registered coded and analyzed without personal identification number according to the scoring manual from EORTC.

Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JCJM, Kaasa S, Klee MC, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw KCA, Sullivan M, Takeda F.

The European Organisation for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute 1993; 85: 365-376.

02

Conditions studied

  • Quality of Life
  • Endometrial Cancer
  • Surgery--Complications
  • Gynecologic Cancer
03

In context

Endometrial Neoplasms

1,325 studies on the registry are indexed under Endometrial Neoplasms; 447 are open to participants now.

This study's enrollment of 64 is below the median of 179 across 321 observational studies indexed under Endometrial Neoplasms.

Browse Endometrial Neoplasms studies →

Lead sponsor

Sahlgrenska University Hospital is the lead sponsor of 259 studies on the registry; 68 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Months and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

All patients planned for primary surgery with robotic technique for endometrial cancer at Department of Obstetrics and Gynecology, Sahlgrenska University Hospital, Gothenburg, Sweden will be asked to participate.

Inclusion criteria

  • Woman over 18 years of age
  • scheduled for primary surgery for histologically verified endometrial cancer (regardless of histological type or degree),
  • tumor clinically restricted to the uterus (presumptive FIGO stage I or II),
  • speaks and reads Swedish,
  • capable of completing the questionnaire independently.

Exclusion criteria

Exclusion Criteria:

  • Clinical or radiological cancer outside the uterus
  • preoperative radio / chemotherapy.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
64 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Quality of Life at 3 months

    Quality of Life at 3 months postoperatively compared to preoperatively The QLQ-C30 is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status / QoL scale, and six single items. Each of the multi-item scales includes a different set of items - no item occurs in more than one scale. Allofthescalesandsingle-itemmeasuresrangeinscorefrom0to100. Ahighscalescore represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems. The attached module EN24 has 3 functional scales and several symptom scales, which scores follows the same system.

    Time frame: 3 months

  2. Quality of Life at 12 months

    Quality of Life at 12 months postoperatively compared to preoperatively The QLQ-C30 is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status / QoL scale, and six single items. Each of the multi-item scales includes a different set of items - no item occurs in more than one scale. Allofthescalesandsingle-itemmeasuresrangeinscorefrom0to100. Ahighscalescore represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems. The attached module EN24 has 3 functional scales and several symptom scales, which scores follows the same system.

    Time frame: 12 months

Secondary outcomes

  1. Anxiety scores

    Scores on GAD7 3 months postoperatively compared to preoperatively Scores 0-21, were a higher scores is associated with more symptoms.

    Time frame: 3 months

  2. Anxiety scores

    Scores on GAD7 12 months postoperatively compared to preoperatively

    Time frame: 12 months

  3. Depression scores

    Scores on PHQ9 3 months postoperatively compared to preoperatively. Scores 0-27 were a high score is associated with more symptoms.

    Time frame: 3 months

  4. Depression scores

    Scores on PHQ9 12 months postoperatively compared to preoperatively. Scores 0-27 were a high score is associated with more symptoms.

    Time frame: 12 months

07

Study locations

1 site
  • 1Department of Obstetrics and Gynecology, Sahlgrenska University Hospital, Gothenburg, Sweden
    Gothenburg, 41345, Sweden
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 12, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04281043
Lead sponsor
Sahlgrenska University Hospital
Collaborators
Hjalmar Svensson Foundation, Assar Gabrielsson Foundation, Göteborg Medical Society
Responsible party
Anna Lindfors (Medical Doctor, Sahlgrenska University Hospital) — Principal investigator
First posted
Feb 21, 2020
Start date
Jun 15, 2019
Primary completion
Jun 15, 2020
Completion
Sep 15, 2021
Last update
Apr 12, 2023

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion